GT200600044A - Polimorfo cci-779 y su uso - Google Patents

Polimorfo cci-779 y su uso

Info

Publication number
GT200600044A
GT200600044A GT200600044A GT200600044A GT200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A GT 200600044 A GT200600044 A GT 200600044A
Authority
GT
Guatemala
Prior art keywords
cci
polymorph
hydrometil
sirolimus
rapamycin
Prior art date
Application number
GT200600044A
Other languages
English (en)
Spanish (es)
Inventor
Subodh S Deshmukh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600044A publication Critical patent/GT200600044A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GT200600044A 2005-02-09 2006-02-07 Polimorfo cci-779 y su uso GT200600044A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65137405P 2005-02-09 2005-02-09

Publications (1)

Publication Number Publication Date
GT200600044A true GT200600044A (es) 2006-11-09

Family

ID=36570939

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600044A GT200600044A (es) 2005-02-09 2006-02-07 Polimorfo cci-779 y su uso

Country Status (19)

Country Link
US (1) US7442707B2 (https=)
EP (1) EP1856130A1 (https=)
JP (1) JP2008530090A (https=)
KR (1) KR20070107030A (https=)
CN (1) CN101115759A (https=)
AR (1) AR052479A1 (https=)
AU (1) AU2006213061A1 (https=)
BR (1) BRPI0607932A2 (https=)
CA (1) CA2595766A1 (https=)
CR (1) CR9257A (https=)
GT (1) GT200600044A (https=)
IL (1) IL184560A0 (https=)
MX (1) MX2007009590A (https=)
NO (1) NO20073725L (https=)
PE (1) PE20060996A1 (https=)
RU (1) RU2007129264A (https=)
TW (1) TW200638932A (https=)
WO (1) WO2006086172A1 (https=)
ZA (1) ZA200706628B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
WO2007067566A2 (en) * 2005-12-07 2007-06-14 Wyeth Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
CN101321770A (zh) * 2005-12-07 2008-12-10 惠氏公司 由雷帕霉素42-酯硼酸酯制备雷帕霉素42-酯的可放大方法
AR058282A1 (es) * 2005-12-07 2008-01-30 Wyeth Corp Forma cristalina purificada de cci-779, un proceso para la preparacion del mismo, un metodo para monitorear la cristalizacion del cci-779, un kit y una composicion farmaceutica que lo comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
TW200824713A (en) * 2006-10-18 2008-06-16 Wyeth Corp Processes for the synthesis of individual isomers of mono-PEG CCI-779
CN102282457A (zh) * 2009-01-21 2011-12-14 拜康有限公司 确定西罗莫司稳定性的方法和制备其稳定形式的工艺
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN109020995A (zh) * 2017-06-12 2018-12-18 鲁南制药集团股份有限公司 一种替西罗莫司的晶型物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
DK1419154T3 (da) 2001-08-22 2006-01-09 Wyeth Corp Rapamycin-29-enoler
EP1419153A1 (en) 2001-08-22 2004-05-19 Wyeth Rapamycin dialdehydes
EP1646635A1 (en) 2003-07-16 2006-04-19 Wyeth Cci-779 isomer c
JP4227649B2 (ja) 2003-08-07 2009-02-18 ワイス Cci−779の位置選択的合成
UA84881C2 (ru) 2003-09-03 2008-12-10 Уайт Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
JP4224115B2 (ja) 2004-04-14 2009-02-12 ワイス ラパマイシン42−エステル誘導体の位置特異的合成

Also Published As

Publication number Publication date
PE20060996A1 (es) 2006-11-13
KR20070107030A (ko) 2007-11-06
NO20073725L (no) 2007-09-05
CN101115759A (zh) 2008-01-30
MX2007009590A (es) 2007-09-12
US20060178392A1 (en) 2006-08-10
IL184560A0 (en) 2007-10-31
EP1856130A1 (en) 2007-11-21
ZA200706628B (en) 2010-01-27
BRPI0607932A2 (pt) 2016-11-08
RU2007129264A (ru) 2009-03-20
US7442707B2 (en) 2008-10-28
JP2008530090A (ja) 2008-08-07
WO2006086172A1 (en) 2006-08-17
CA2595766A1 (en) 2006-08-17
AR052479A1 (es) 2007-03-21
TW200638932A (en) 2006-11-16
AU2006213061A1 (en) 2006-08-17
CR9257A (es) 2007-11-23

Similar Documents

Publication Publication Date Title
WO2007028135A3 (en) Imidazopyridine compounds
TW200510428A (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
CL2010000320A1 (es) Un compuesto 8-(1,3-dihidro-isoindol-2-ilmetil)-2,9-dihidro-1,2,7,9-tetraaza-fenalen-3-ona, como inhibidor de parp; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2007002188A1 (es) Compuestos derivados de heteroarilaminas; procedimiento de preparacion; composicion farmceutica; y uso del compuesto para tratar el crecimiento celular anormal.
GT200500085A (es) Sintesis regioespecifica de derivados de 42-ester de rapamicina
WO2009060835A1 (ja) 新規ユビキリン結合性小分子
CL2012000707A1 (es) Compuestos derivados de [5-(pirrolo[1,2-c][1.2.3]triazin-7-il)tetrahidrofuran-2-il]metanol; composición farmacéutica; y su uso para el tratamiento de la hepatitis c.
WO2007084728A3 (en) 2-imino-benzimidazoles
WO2004066912A3 (en) Anti-inflammatory compositions and uses thereof
CL2012001027A1 (es) Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek.
WO2007061923A3 (en) Glucokinase activators
HN2009000784A (es) Dihidropirazolonas sustituidas
BRPI0613429A2 (pt) inibidores de histona desacetilase
CR20110223A (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGÍA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
ECSP099694A (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
BRPI0720972B8 (pt) compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos
CR10628A (es) Compuestos quimicos
ECSP11011181A (es) Compuestos orgánicos
BR112012008889A2 (pt) compostos de espiropiperidina e uso farmacêutico dos mesmos para tratar diabetes
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
ECSP088932A (es) Nuevos compuestos químicos
WO2008096001A8 (en) Hcv inhibiting macrocyclic phenylcarbamates
UY28695A1 (es) Derivados de difenilazetidona
PE20080138A1 (es) Procesos para preparar conjugados de polietilen glicol solubles en agua de inmunosupresores macrolidos